Life Sciences Archive » October, 2020

Life Sciences - October, 2020

354 articles

• Alabama Justices Urge High Court To Overturn Roe
• Feds Pressed On Bid To Nix Gilead HIV Patent Counterclaims
• COVID-19 Drugmaker Leads 2 Latham-Led Cos.' $373M IPOs
• Cozen O'Connor Adds 2 Ex-Kilpatrick IP Attys
• Pfizer Unit Agrees To $4.2M Enviro Remediation In NJ
• Rival Lab Co.'s CEO Stole Trade Secrets As Student, Suit Says
• Fresenius Fights $11.5M Atty Fee Bid In Medicare Case
• Gov't Contracts Of The Month: Weapons, 5G, Virus Treatments
• FDA Says Groups Can't Sue Over Drug To Reduce Cattle Gas
• Wyden Leans On Trump To Enforce N. American Trade Deal
• 3 Reasons Medical Offices Remain Attractive Amid Pandemic
• High Times Subsidiary Says Fake Urine Maker Owes Royalties
• Mylan, Pfizer Unit Merger Clears Final Hurdle With FTC Deal
• Book Review: Did The High Court Cause Mass Incarceration?
• Taxation With Representation: Latham, Pillsbury, Baker
• Should GCs Fear The DOJ's Power To Bankrupt?
• Cross-Border Discovery Trends 1 Year After 2nd Circ. Ruling
• Decoupling From China: Part 3 — Oversight And The Election
• UK Litigation Roundup: Here's What You Missed In London
• Imerys Gets Court OK For $223M Stalking Horse Bid
• AstraZeneca Gets $287M Vaccine Contract From Army
• Hemostemix Says Data Co. Is Holding Drug Trial Data Captive
• Pa. College Dodges Claims Over Student's Medical Pot Use
• DOJ, Medtronic Agree To $9M Deal Over Restaurant Kickbacks
• 3 IPOs Exceed $1B Amid Market Volatility, Others Delay
• Decoupling From China: Part 2 — Security Requirements
• Coronavirus Litigation: The Week In Review
• 9th Circ. Sinks Pharma Cos.' Suit Against Hawaii AG
• FTC Says Shkreli Can't Relitigate Authority Challenge
• 3rd Circ. Backs WashU's $32M Patent Contract Win
• Persuasion Skills Attys Can Learn From Political Speeches
• Drugmaker In IP Fight With Mylan Calls EPO Ruling 'Irrelevant'
• Biogen Says Fed. Circ. Patent Ax Ruling 'Breaks New Ground'
• NY AG's Opioid Epidemic Jury Trial Set For Early 2021
• Feds Defend Warrant In $94M Drug Return Fraud Appeal
• Eli Lilly Scores $375M For COVID-19 Treatment
• Fight Over Sackler Deal On Hold For Purdue Ch. 11 Plan Talks
• SEC Settles Suit Over Allegedly Misleading COVID-19 Claims
• Dems Urge Hearing On 'Outsized' DOD Role In Vaccine
• Decoupling From China: Part 1 — Legislation And Funding
• Courts Shouldn't Consider Bodily Injury Claims In Opioid Suits
• Zimmer Says No Sex Bias Behind Exec's Severance Denial
• Reflections On My 1st Judicial Election Amid Racial Tensions
• Pharmacies Sue FDA Over Compounded Drug Agreements
• Drugmaker Wins Appeal On Myeloma Treatment Authorization
• AGs In A Pandemic: Ellison Talks Minnesota Housing
• 3M Makes Deal With Ex-Marine Over Massive N95 Mask Scam
• IP Profs Want Justices to Resolve Split Over Jury Verdicts
• EPA Greenlights Dicamba Use After 9th Circ.-Ordered Review
• Real Estate Firms Lean Bearish, Eye Logistics And Biotech
• NJ Justices Question J&J Taxes On Coverage Beyond State
• Ind. Appeals Court Mulls Venue In Medtronic Contract Row
• Mass. High Court Says Pot Patients Cannot Get Reimbursed
• Justices Told FCA Circuit Split Poses 'Far-Reaching' Threat
• Alsup Grants Sanctions, Bemoans Ex-Player's MLB 'Crusade'
• Calif. Pot Testing Lab Says Mayor Sought Bribe For Permit
• Purdue Creditors Object To Sackler Part Of $8B DOJ Deal
• J&J Flags 'Moral Hazard' In Imerys' Del. Ch. 11 Disclosure
• Coronavirus Regulations: A State-By-State Week In Review
• High Court To Mull Taking Up Abortion Case This Week
• Judge Wants New Bellwether List In Cook Vein Filter MDL
• Key Gov't Tools For Addressing National PPE Shortages
• Weighing Litigation Vs. Arbitration Amid Court Disruptions
• Exact Sciences Buys Cancer Detection Cos. For Up To $2.56B
• Greenberg Traurig Snaps Up IP Partner In LA From Jones Day
• J&J, 3M Urge Congress To Back PTAB Discretionary Denials
• AIG Sues McKesson Over Opioid Litigation Coverage
• COVID-19 Drug Developer Joins IPO Pipeline In Packed Week
• Judge Lourie Reflects On IP's Rise From 'Backwater' Of Law
• 2nd Circ. Won't Revive Apotex's Unfair Competition Suit
• Teva, Cooper Slam Bid To Send IUD Defect Suits To Calif. MDL
• Feds Float Drop Of Preterm Birth Drug Approval, Women Say
• Rakoff Opens SDNY Fraud Trial With Dig At Pence On Virus
• 'Cobra Sexual Energy' Maker Inks $100K Deal In False Ad Suit
• Avoiding Shareholder Class Actions After FDA Drug Denials
• 1st Circ. Backs 4-Year Sentence Of Insys Opioid 'Drug Pusher'
• How Attys Can Guard Against Rising Settle-And-Sue Claims
• Pfizer Pushes 2nd Circ. To Ditch Patients' Lipitor Claims
• Baker McKenzie, Ropes Steer Up To $4B Bayer-AskBio Deal
• Chevron Deference's Future In Doubt If Barrett Is Confirmed
• Lannett Drug Price-Fixing Settlement Gets Del. Judge's OK
• Business Groups Rally Behind J&J's $465M Opioid Appeal
• 9th Circ. Judge Doubts Monsanto's $25M Roundup Argument
• Ropes, Latham Steer Cancer-Focused Biotech's $120M Float
• Pa. Stores Accused Of Wrongly Charging Sales Tax On Masks
• Health Hires: Polsinelli, Akerman
• Lens Buyers Float $30.2M Deal For ABB Optical To Leave Suit
• UK Litigation Roundup: Here's What You Missed In London
• Law Firm Tips For Attracting, Retaining Attys During Pandemic
• Gilead's Remdesivir Wins 1st FDA Full Approval For COVID-19
• FDA Advisers Fear Coronavirus Vaccines Won't Help Enough
• Walmart Sues Feds To Get Ahead Of Possible Opioid Suit
• Whistleblower Cheat Sheet: Trump Faces A New Wave
• IP Atty Asks 9th Circ. To Revive Bausch Whistleblower Suit
• Shkreli Says FTC Can't Nix Challenge To Authority
• Invisalign Maker Expands Scanner Patent Fight To Texas
• AbbVie Gets AndroGel Monopoly Case Moved To NJ
• Finding A Path Forward To Regulate The Legal Industry
• Vaping And COVID-19: Plausibility And Causality
• Coronavirus Litigation: The Week In Review
• Loeb & Loeb Adds Ex-McGuireWoods IP Litigator To NY Office
• CORRECTION: Gene Therapy Startup Gets $107M In Series A Round
• Insurer Says Judge Erred In Sending Virus Suit To State Court
• Calif. High Court Won't Review $21M Monsanto Verdict
• Eli Lilly Fights To Challenge Teva Migraine IP Despite Deal
• Cybersecurity Co. McAfee Leads 3 IPOs With $740M Debut
• Amgen Cholesterol IP Suit Restarts As EPO Decision Looms
• Lawyering While Parenting: A Day In A Dad's Pandemic Life
• Judiciary Panel Sends Barrett Nomination To Full Senate
• 3 False Claims Act Takeaways From Purdue's Opioid Deal
• Meet The Attys Guiding Purdue On $8B DOJ Opioid Plea Deal
• Where DOJ's Opioid Blitz Stands After Purdue's Criminal Case
• Sackler Factor Could Sink Purdue's $8B Opioid Deal With DOJ
• 1-800 Contacts Gets Final Approval On $15M Antitrust Deal
• Nevada Pot Regulators Collect $63K In Fines Over Violations
• Coronavirus Regulations: A State-By-State Week In Review
• Whistleblower's Claims Against ICE Contractor Set For Trial
• Atty Rips Feds' 'Unbridled Attempt' To Steer China Tariff Suits
• 8 Firms Steer 5 Blank-Check IPOs Exceeding $1.3B Total
• DOJ Can Jump Into Teva Suit, But Only On Limited Basis
• Union Funds Lose Bid To Pause Akorn's Ch. 11 Confirmation
• Fed. Circ. Ruling Is Troubling For Generic Drug Manufacturers
• Lawyering While Parenting: A Day In A Mom's Pandemic Life
• 2nd Circ. Gives Teeth To Omnicare Securities Fraud Standard
• Pa. Justices OK State's Jurisdiction Over J&J In Mesh Cases
• Medical Pot Patient Sues Pa. County After Failed Drug Test
• Supplement Makers Must Face Joint Pill False Ad Suit
• 5 States Poised To Legalize Pot At The Ballot
• 9th Circ. Revives Abbott Labs Worker's Age Bias Claim
• Purdue To Pay $8B In Penalties In DOJ Opioid Plea Deal
• Valeant Securities Suit Was Launched On Time, 3rd Circ. Told
• Scientist Says USCIS Ignored Reputation Of Washington Univ.
• Opioid Settlements Stymied By Atty Fee Demands, AGs Say
• Atty Says Medical Device GC Ousted Him For Not Hiding Cash
• Full Fed. Circ. Skips Split Immunity Ruling In Cancer IP Row
• Sanofi Wants Antitrust Claims Over Insulin Pen Pared Down
• Wilson Sonsini Taps New Europe Business Development Head
• Daiichi Faces Patent Suit Over New Breast Cancer Drug
• DC Circ. Won't Rethink HHS Cuts To Medicare Drug Program
• 2 Fed. Circ. Rulings Show Importance Of Correct Inventorship
• Health Care Co. Objects To Nov. Trial In Cancer Patent Fight
• Abbott Says Ex-Worker Using TMs To Sell COVID-19 Tests
• Questions Raised By FDA's New Lab Test Policy
• Trulieve Slams 'Ham-Fisted' Sanction Bid In Hiring Dispute
• 10th Circ. Upholds IRS Summons For State Info On Pot Cos.
• 5 Cost-Cutting Strategies For Corporate Legal Departments
• Judge Tosses Co.'s Ch. 11 Filing Over Canadian Pot Plans
• WTO Holds Off On Waiving IP For COVID-19 Vaccines
• 10 Firms To Steer 8 IPOs Exceeding $2B As October Stays Hot
• Justices Urged Not To Let Arbitrator Decide Venue Question
• Preparing The Next Generation Of Female Trial Lawyers
• Mentorship Is Key To Fixing Drop-Off Of Women In Law
• Female Attorneys Gain Ground In Battle For Clerkships​
• What BigLaw Can Do To Actually Retain Female Attorneys
• Wearing Natural Hair In BigLaw
• These Firms Have The Most Women In Equity Partnerships
• 6 Russian Officers Indicted Over Massive Cyberattack
• Trump Admin. Hit With Another Suit Over Vaccine Contracts
• High Court Won't Hear FDA Stimulant Seizure Suit
• How A Biden Administration Would Shape IP Policy
• 5 Ways Firms Can Avoid Female Atty Exodus During Pandemic
• In Their Own Words: Being A Woman In BigLaw
• Law360's Glass Ceiling Report: What You Need To Know
• Glass Ceiling Report: How Does Your Firm Measure Up?
• CVS, Walgreens Tapped To Dispense COVID-19 Vaccine
• Teva, Workers Reach Deal To Settle 401(k) Fee Suit
• Purdue, Sacklers Say Atty-Client Privilege Shields Documents
• Biotech, Med Device Companies Price 6 IPOs Totaling $712M
• Kilpatrick Townsend Adds Life Sciences Team From DLA Piper
• Ohio Pot Co. Wins Second Shot At Dispensary Licenses
• Texas Cotton Farmers Get Pesticide Drift Suit Partially Revived
• Patients Say Ill. Allergan Ruling Is Irrelevant To Implant MDL
• Whistleblower Firm Sued Over Fees In GlaxoSmithKline Suit
• Full Fed. Circ. Won't Review Inventorship Row Over Cancer IP
• Pot Co. Cancels $3.9M Stock Sale Over Short Seller Fears
• High Court Faces Preemption Dilemma In Drug Benefits Case
• Consumer Slams ViSalus Trial Redo Bid In $925M TCPA Row
• Thiel-Backed Blank-Check Co. Leads 2 IPOs Raising $635M
• How The State And Local Regulatory Landscape Is Expanding
• Lowenstein Sandler Adds Antitrust Partner Jonathan Lewis
• Simpson Reps Blackstone In $14.6B BioMed Realty Deal
• St. Jude Can't Revive Heart Valve IP Challenge At Fed. Circ.
• Coronavirus Litigation: The Week In Review
• Ropes & Gray Nabs Health Partner From Hogan Lovells
• Pot Co. Says Stock Buys Disprove $144M 'Sham' Asset Plot
• Trump Admin. Sued For Withholding Virus Vaccine Contracts
• US Merck Prevails In Vaccine IP Battle Against Pfizer
• State AGs Bash DOJ's Proposed Opioid Deal With Purdue
• Top Mallinckrodt Creditor Opposes Del. Ch. 11 Strategy
• Whistleblower In Merit Medical Case Gets Closure, And $2.7M
• Allergan, Teva Sanctioned For Flouting Opioid MDL Discovery
• Justices Urged To Block Arbitration In Dental Suppliers' Fight
• Green Groups Call EPA Chemical Emissions Rule 'Weak'
• New Mexico Can't Block Nonresidents' Medical Pot Access
• Man Allergan Texted About Botox Seeks Cert. In TCPA Suit
• AstraZeneca Inks $486M COVID-19 Antibody Deal With Gov't
• WuXi PharmaTech Dodges Securities Suit
• GNC Gets Ch. 11 Plan Confirmed After $780M Stores Sale
• Chancery Ignored Precedent By Axing Suit, Del. Justices Told
• J&J Keeps Pushing For Destruction Of Asbestos ERISA Suit
• 12 Firms Vie For Lead In Kodak Investors' Stock Trading Suits
• How COVID-19 May Rattle Companies' Supply Chains
• Fed. Circ. OKs Ax Of Medtronic Suit In $112M Patent Dispute
• Lawyers Must Fight Voter Suppression This Election Season
• FTC, State AGs Say Humira Judge Botched Actavis Reading
• What Patent Prosecution Market Size Means For Cos., Counsel
• Target Beats Suit Over Pharmacy Prescription Flub
• Patent Law Is Just The Beginning For High Court In Arthrex
• Shire Owes $45M Milestone After Life Science Acquisition
• Tomax Seeks To Duck Blame Over Failed $57M PPE Deal
• Humira Buyers Get Backing Against AbbVie's 'Patent Thicket'
• High Court PBM Case Could Be Turning Point In 20-Year Fight
• Fed. Circ. Backs Sanofi, Regeneron PTAB Win Over Amgen
• J&J Strikes $5B Deal Pushing 3,000 Opioid Suits Toward End
• Predictions For High Court Review Of Arthrex
• Why Online Mediation May Be Here To Stay
• 'Trump Cards' For Drug Discounts Look Unlawful, Dems Say
• Mass. Pot Shop Can't Shake Recreational Licensing Loss
• Coronavirus Regulations: A State-By-State Week In Review
• Mallinckrodt Plans $1.6B Opioid Trust In $5.3B Del. Ch. 11
• Theranos Founder Elizabeth Holmes Can't Shake New Charges
• Justices Pass On Transgender Inmate's Gender Surgery Suit
• Mylan Can't Expedite Novartis Blood Transfusion IP Fight
• High Court Rejects Ex-NFL Player's Pot Legalization Bid
• 3 Firms Steer PE Deal For $2.25B Chemical Products Maker
• Supreme Court Will Decide If PTAB Judges Are Constitutional
• Court Hints Boston May Win Costs In False Drug Test Suit
• J&J Opens Appeal By Assailing 'Radical' $465M Opioid Verdict
• Eye Device Maker Gets Rival Product Blocked During IP Fight
• Allergan Escapes Ill. Suit Over Defective Breast Implants
• Drug Cos. Fight Class Cert. For 'Opioid Babies' In MDL
• Prosthetic Maker Reaches Deal Over FTC's Merger Unwinding
• 9th Circ. Revives CVS Joint Pain Pills False Ad Suit
• COVID-19 IP Catch-Up: Moderna Promises & Ed Sheeran
• MiMedx Investors Get Initial OK For Fraud Deal, $3.5M In Fees
• Biopharma Co. Leads Pack Of 5 IPOs Totaling $650.8M
• Texas Justices Bounce Back Fen-Phen Atty Malpractice Fight
• Health Hires: Goodwin, Greenberg Traurig
• MVP: White & Case's Robert Milne
• Opioid MDL Bellwether Trial Delayed Amid COVID-19 Fears
• Early Takeaways From SEC's FY 2020 Fraud Enforcement
• Negotiation Class Wants 6th Circ. Full Review In Opioid MDL
• Clients Have The Power To Promote Wellness At Law Firms
• Cannabis Regs: Mich. To Ease Recreational Pot Licensing
• Pandemic Can't Delay Landmark Opioid Trial, Judge Told
• High Court Punts FDA Bid To Revive Abortion Pill Restriction
• BioMedomics Faces $6.1M Suit Over COVID-19 Antibody Test
• Senate Bill Would Sanction Foreign COVID-19 IP Hackers
• Del. Judge Won't Invalidate 'Smile Designer' Patents
• Stryker's Trial Win Over Surgery Death Upheld On Appeal
• Moderna Won't Enforce COVID-19 Patents During Pandemic
• Becton Dickinson Settles Watchdog's Race Bias Probe
• Costco Dodges Suit Over Roundup Marketing
• Takeda Asks 2nd Circ. To Flip Actos Rulings
• Judge Says Dentist's Virus Suit Should Return To State Court
• Appellate Courts Should Welcome Well-Crafted Amicus Briefs
• What To Know About FDA's 'Intended Use' Proposed Rule
• Allergan Implant Patients Say State Claims Should Proceed
• Minerva Takes Assignor Estoppel Fight To Supreme Court
• Vt. Legalizes Recreational Cannabis Sales, Imposes Taxes
• CVS Accused Of Stiffing Arizona Pharmacists On OT
• Pence, Harris Brawl Over Trump's Judges, Bigger High Court
• Gilead Accused Of Antitrust Scheme Over HIV Meds
• Dems Float Bill To Block $250M HHS COVID-19 Ad Campaign
• Veterans Urge 9th Circ. To Hear Challenge To DEA's Pot Status
• Two TPG-Backed SPACs Among 5 Raising Total $1.8B In IPOs
• Calif. Consumers Want 2nd Shot At Lipitor Antitrust Subclass
• Florida Tells State High Court That Pot License Law Is Valid
• MVP: Sullivan & Cromwell's Matthew Hurd
• Regeneron Says Feds' Kickback Theory Makes Charity Illegal
• MVP: Weil Gotshal's Derek Walter
• Generics Worry Fed. Circ. Blew Up 'Routine' Labeling Practice
• Walmart Is Sued Over Intoxicated Driver's Crash That Killed 3
• 4 Developments As FDA Vaccine Guidance Stokes Trump's Ire
• NY Prof. Gets Prison For Pilfering Cancer Grant Money
• Investor Wants Attys Sanctioned In CBD Co. Securities Suit
• Biotech Co. Wants $881M Cannabinoid IP Fight Arbitrated
• Ex-Theranos CEO Slams Safeway, Walgreens Fraud Charges
• Humira Buyers Ask 7th Circ. To Revive 'Patent Thicket' Case
• Avadel Pharma Gets OK For Liquidation Plan After IRS Deal
• Mylan Says 3rd Circ. Ruling Can't Boost EpiPen Antitrust Suit
• WTO Offers Cautious Optimism On COVID-19 Trade Recovery
• Coronavirus Regulations: A State-By-State Week In Review
• Zest Soap Maker Gets Approval For Ch. 11 Liquidation Plan
• Storage Tank Co. Can't Nix Destroyed Embryo Suit
• What Hiring Law Firms Should Consider Instead Of Grades
• How To Navigate A Hardening D&O Insurance Market
• 1st Circ. Presses Ex-Aveo CFO On Candor With Analyst
• MVPs: Latham's Daniel Brown And Ken Schuler
• 4 Firms Guide $850M Tie-Up Of Medical Products Cos.
• Justices Eye Arkansas PBM Law's Impact On Workers
• Fed. Circ. Mulls New Trial In Vectura's $107M Inhaler IP Win
• Drug Distributors Fear 'Super-Spreader' Trial In Opioid MDL
• SDNY Jury Trial Of Ex-MiMedx Execs Set For End Of October
• Key Highlights As House Dems Drop Hammer On Drugmakers
• Former Desmarais Atty Starts New PTAB Firm
• Justices Won't Hear Widow's Appeal Over Heart Drug Warning
• 8 More IP Cases The Justices Rejected At 1st Conference
• Pot Co. Trulieve Accused Of Hiding Discovery In Hiring Row
• Chancery Orders Walmart To Turn Over Opioid Oversight Docs
• Pfizer, Regeneron Hit With Patent Suits Over COVID-19 Tech
• High Court To Weigh States' Ability To Rein In Drug Middlemen
• MVP: Covington & Burling's Jennifer Plitsch
• FCA Materiality Standard's Odd Application To Payment Terms
• Justices Delay Arthrex Petitions, But Deny Expansion Bids
• Trump Should Revisit Flawed Plan To Lower Drug Prices
• Cancer-Focused Firm Leads 4 IPO Launches Totaling $353M
• GSK Can't Get High Court Review In Avandia Marketing Fight
• Justices Skip Opioid Treatment Case Disputing PTAB's Power
• Trustee Flags Gaps In J&J Talc Supplier's Ch. 11 Plan
• Judging A Book: Schroeder Reviews 'Collegiality'
• Now Is The Time To Go Digital With Compliance Training
• 2 Firms Drive $13.1B Heart Disease Treatment Developer Deal
• Law360 MVP Awards Go To Top Attorneys From 76 Firms
• House Panels Launch Probe Into DOD Virus Aid Bill Spending
• Simpson Thacher Reps Academy For Undersized $203M IPO
• Abbott Shakes ERISA Suit Over Pilfered Retirement Savings
• J&J Unit Wins Block Against Seller Of Counterfeit Implants
• How Rookies Should Prep For A Unique Supreme Court Term
• Health Hires: Covington, Baker Donelson, Wiley Rein
• 1 Firm Seizes Spotlight Amid September's IPO Surge
• What One Scrapped Opinion Might Say About Judge Barrett
• Patents A Key Focus As Drug-Pricing Debate Intensifies
• Supreme Court Cheat Sheet: The Biggest Cases To Watch
• Canadian Pot Co. Can't Slip Suit Over $144M 'Sham' Asset Buy
• Dialysis Co. Agrees To $853M Sale Amid Investor Class Deal
• Amarin Tells Fed. Circ. Vascepa Patents Didn't Get Fair Shot
• COVID-19 IP Catch-Up: Reflecting On Priorities, Shifting Trials
• Medicare Entitlement Rulings Help Bankrupt Health Providers
• The Heeding Presumption's Evolving Role In Pharma Suits
• Agrify Corp. Gains New GC From Ocean Spray
• Overcoming The Pandemic's Hurdles To Pro Bono Work
• UK Litigation Roundup: Here's What You Missed In London
• GOP Vows Virus Infections Won't Slow Barrett Confirmation
• Split Fed. Circ. Revives GSK's $235M Win Against Teva
• Trump Tests Positive For COVID-19
• Fla. Nursery Says Drug Laws Don't Apply To State Licenses
• Ohio High Court Holds Amazon Not Liable For Teen's Death
• 5 Health Cases Attys Should Know As High Court Term Starts
• Pfizer Shorted NYU On Cancer Drug Royalties, Suit Says
• Pot Co. Ayr Invests $39M In Ohio And Pa. Cannabis Markets
• Shareholders Can't Fish Through Teva Texts, Judge Told
• Akorn Seeks Del. Ch. 11 OK For $9M Stockholder Suit Deal
• DC Circ. Studies What Costs Indian Health Service Must Cover
• RICO Claims Trimmed In SF Opioid Case
• Teva Unit Tells High Court Not To Take Up Horizon's IP Loss
• J&J Cos. Sue To Block Exec's Move To Smith & Nephew
• ​​​​​​Drug Pricing Site Says Trump's Order Supports Antitrust Suit
• Importers Call For CIT Panel To Handle China Tariff Challenge
• Deals Rumor Mill: Asda, Lonza, Reckitt Benckiser
• College Coronavirus Q&A: Duke's General Counsel
• Bristol-Myers Squibb Escapes Investor Suit Over Clinical Trial
• Mass. Priest Targeted By SEC Says Trades Were By The Book
• Best Practices For Presenting Exhibits In A Remote Deposition